1 / 2

Comparative Efficacy Analysis of Telaprevir Treatment in Hepatitis C Genotype 1a Patients

This study compares the response rates of telaprevir treatment in patients with Hepatitis C genotype 1a based on their prior treatment response. Results show a superiority rate of 54% and non-inferiority rate of 43%. The analysis includes 208 patients with a history of peginterferon/ribavirin treatment, indicating varying response rates for RVS12 based on prior treatment outcomes. These findings offer insights into the effectiveness of telaprevir therapy in this patient population.

britain
Télécharger la présentation

Comparative Efficacy Analysis of Telaprevir Treatment in Hepatitis C Genotype 1a Patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RVS12 en ITT * Non infériorité et supériorité par rapport aux taux de réponse au traitement “historique” du traitement télaprévir + peginterféron/ribavirine Supériorité : 54 %* Non-infériorité : 43 %* 191/208 165/172

  2. RVS12 en fonction de la réponse au traitement antérieur chez les patients infectés par le VHC de génotype 1a 59/64 52/56 14/15 13/13 11/11 10/10 40/50 39/42

More Related